115 related articles for article (PubMed ID: 38438140)
1. Longitudinal evaluation of adverse events due to steroid use in primary immune thrombocytopenia: A population-based study.
Wang JD; Ku FC; Chiang IJ; Ku MY; Chen YM; Chien LN
Br J Haematol; 2024 May; 204(5):1986-1993. PubMed ID: 38438140
[TBL] [Abstract][Full Text] [Related]
2. A megakaryocyte morphological classification-based predictive model for steroid sensitivity in primary immune thrombocytopenia.
Zhu J; Chen R; Zhao S; Zhu L; Li X; Xie M; Ye X
Platelets; 2020 Oct; 31(7):939-944. PubMed ID: 31875757
[TBL] [Abstract][Full Text] [Related]
3. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
[TBL] [Abstract][Full Text] [Related]
4. Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study.
Chen HL; Shen LJ; Hsu PN; Shen CY; Hall SA; Hsiao FY
J Rheumatol; 2018 Jan; 45(1):83-89. PubMed ID: 29142034
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
Tripathi AK; Shukla A; Mishra S; Yadav YS; Yadav DK
Int J Hematol; 2014 Apr; 99(4):413-7. PubMed ID: 24526570
[TBL] [Abstract][Full Text] [Related]
6. Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database.
Mezaache S; Derumeaux H; Ferraro P; Capdepon P; Steinbach JC; Abballe X; Palas D; Saichi N; Desboeuf K; Lapeyre-Mestre M; Sailler L; Moulis G
Eur J Haematol; 2017 Oct; 99(4):344-349. PubMed ID: 28692146
[TBL] [Abstract][Full Text] [Related]
7. Effect of steroids on the activation status of platelets in patients with Immune thrombocytopenia (ITP).
Bhoria P; Sharma S; Varma N; Malhotra P; Varma S; Luthra-Guptasarma M
Platelets; 2015; 26(2):119-26. PubMed ID: 24617442
[TBL] [Abstract][Full Text] [Related]
8. Incidence of immune thrombocytopenia in Taiwan: a nationwide population-based study.
Hung GY; Lee CY; Yen HJ; Lin LY; Horng JL
Transfusion; 2018 Nov; 58(11):2712-2719. PubMed ID: 30311951
[TBL] [Abstract][Full Text] [Related]
9. Bone mass and biochemical markers of bone turnover in children and adolescents with chronic immune thrombocytopenia: relation to corticosteroid therapy and vitamin D receptor gene polymorphisms.
Tantawy AA; El Bostany EA; Matter RM; El Ghoroury EA; Ragab S; El Sherif NH
Platelets; 2013; 24(4):282-7. PubMed ID: 22671537
[TBL] [Abstract][Full Text] [Related]
10. Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
Donga PZ; Bilir SP; Little G; Babinchak T; Munakata J
J Med Econ; 2017 Nov; 20(11):1200-1206. PubMed ID: 28882075
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Antiphospholipid Antibodies in Patients With Immune Thrombocytopenia and Correlation With Treatment With Steroids in North Indian Population.
Dayama A; Dass J; Mahapatra M; Saxena R
Clin Appl Thromb Hemost; 2017 Sep; 23(6):657-662. PubMed ID: 27067744
[TBL] [Abstract][Full Text] [Related]
12. Association between P-Selectin Autoantibody Positive and Response to Steroid Treatment in Newly Diagnosed Immune Thrombocytopenia Patients.
Wang L; Wang DD; Jiao RY; Liu CX; Hou YQ; Qin H; He HJ
Acta Haematol; 2022; 145(5):499-504. PubMed ID: 35405676
[TBL] [Abstract][Full Text] [Related]
13. Immune thrombocytopenic purpura increased risk of subsequent pancreatitis: A Nationwide population cohort study.
Wu SC; Lin SF; Fang CW; Tsai IJ; Yang WC
Sci Rep; 2019 Nov; 9(1):16923. PubMed ID: 31729447
[TBL] [Abstract][Full Text] [Related]
14. Incidence and outcomes of refractory immune thrombocytopenic purpura in children: a retrospective study in a single institution.
Ito M; Yagasaki H; Kanezawa K; Shimozawa K; Hirai M; Morioka I
Sci Rep; 2021 Jul; 11(1):14263. PubMed ID: 34253777
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients.
Yu J; Xu Z; Zhuo Y; Wei H; Ye Y; Xu Q; Li Y; Yu L; Feng W; Hong P; Zhang K
Hematology; 2021 Dec; 26(1):956-963. PubMed ID: 34871524
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Multicenter Trial Comparing Low-Dose Prednisolone Versus Observation for Prevention of Recurrences in Adult Immune Thrombocytopenia.
Pirunsarn A; Kijrattanakul P; Chamnanchanunt S; Polprasert C; Rojnuckarin P
Clin Appl Thromb Hemost; 2018 Sep; 24(6):867-873. PubMed ID: 29614865
[TBL] [Abstract][Full Text] [Related]
17. Increased thrombopoietin levels in idiopathic thrombocytopenic purpura patients with a poor response to steroid therapy.
Sakane Y; Wada H; Kazuyo H; Shimura M; Nakasaki T; Katayama N; Nishikawa M; Deguchi K; Mori Y; Mori Y; Shiku H; Tahara T; Kato T
Blood Coagul Fibrinolysis; 1998 Jun; 9(4):315-21. PubMed ID: 9690802
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
[No Abstract] [Full Text] [Related]
19. Cytokine gene polymorphism [tumor necrosis factor-alpha (-308), IL-10 (-1082), IL-6 (-174), IL-17F, 1RaVNTR] in pediatric patients with primary immune thrombocytopenia and response to different treatment modalities.
Mokhtar GM; El-Beblawy NM; Adly AA; Elbarbary NS; Kamal TM; Hasan EM
Blood Coagul Fibrinolysis; 2016 Apr; 27(3):313-23. PubMed ID: 27007229
[TBL] [Abstract][Full Text] [Related]
20. Immune thrombocytopenia and risk of stroke: Evidence from a nationwide population-based cohort study.
Chen HY; Lee WK; Chang R; Hung YM; Hsu CY; Shih YH; Chen JS
Int J Stroke; 2023 Apr; 18(4):408-415. PubMed ID: 36073612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
